Literature DB >> 28944193

The ocular toxicity and pharmacokinetics of simvastatin following intravitreal injection in mice.

Dennis Y Tse1,2, Seong Jae Kim3, Inyoung Chung3, Feng He4, Theodore G Wensel4, Samuel M Wu1.   

Abstract

AIM: To investigate the retinal toxicity and pharmacokinetics of simvastatin intravitreally injected into mice.
METHODS: Forty-eight 6-8-week-old C57BL/6J mice were used in this study. Simvastatin was intravitreally injected into the right eye of each mouse; the left eye was injected with vehicle and was used as a control. Bilateral dark-adapted electroretinography (ERG) was performed 1 and 7d following injection. Histology was examined using a combination of light, fluorescence and electron microscopy. High-performance liquid chromatography (HPLC) was used to determine the decay in the retinal simvastatin concentration.
RESULTS: ERG revealed no significant changes in the simvastatin-injected eyes compared to control. Histologic studies showed normal retinal morphology in eyes injected with simvastatin up to a final vitreal concentration of 200 µmol/L. No significant changes in the number of photoreceptors, bipolar cells or ganglion cells were found. The retinal simvastatin concentration decayed exponentially, with a half-life of 1.92-2.41h.
CONCLUSION: Intravitreal injection of up to 200 µmol/L simvastatin produced no signs of adverse effects in the mouse retina. Simvastatin reaches the retina shortly after intravitreal injectionand has a short half-life.

Entities:  

Keywords:  electron microscopy; electroretinography; high-performance liquid chromatography; intravitreal injection; retina; simvastatin

Year:  2017        PMID: 28944193      PMCID: PMC5596219          DOI: 10.18240/ijo.2017.09.05

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  48 in total

Review 1.  Enhancement of ocular drug penetration.

Authors:  H Sasaki; K Yamamura; T Mukai; K Nishida; J Nakamura; M Nakashima; M Ichikawa
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  1999       Impact factor: 4.889

2.  The relationship between statin use and open-angle glaucoma.

Authors:  Joshua D Stein; Paula Anne Newman-Casey; Nidhi Talwar; Bin Nan; Julia E Richards; David C Musch
Journal:  Ophthalmology       Date:  2012-06-21       Impact factor: 12.079

3.  Statins and the long-term risk of incident age-related macular degeneration: the Blue Mountains Eye Study.

Authors:  Jennifer S L Tan; Paul Mitchell; Elena Rochtchina; Jie Jin Wang
Journal:  Am J Ophthalmol       Date:  2006-12-20       Impact factor: 5.258

4.  Cone photoreceptor function loss-3, a novel mouse model of achromatopsia due to a mutation in Gnat2.

Authors:  Bo Chang; Mark S Dacey; Norm L Hawes; Peter F Hitchcock; Ann H Milam; Pelin Atmaca-Sonmez; Steven Nusinowitz; John R Heckenlively
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-11       Impact factor: 4.799

5.  The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells.

Authors:  B Kwak; F Mulhaupt; N Veillard; G Pelli; F Mach
Journal:  Swiss Med Wkly       Date:  2001-01-27       Impact factor: 2.193

6.  Statins modulate heat shock protein expression and enhance retinal ganglion cell survival after transient retinal ischemia/reperfusion in vivo.

Authors:  Christian Schmeer; Adriana Gámez; Svetlana Tausch; Otto W Witte; Stefan Isenmann
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-06-19       Impact factor: 4.799

7.  Safety and pharmokinetics of triamcinolone hexacetonide in rabbit eyes.

Authors:  Muhammad M Abd-El-Barr; Thomas A Albini; Petros E Carvounis; Feng He; Roberta P A Manzano; Patricia Chevez-Barrios; Theodore G Wensel; Samuel M Wu; Eric R Holz
Journal:  J Ocul Pharmacol Ther       Date:  2008-04       Impact factor: 2.671

8.  Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection.

Authors:  H W Kwak; D J D'Amico
Journal:  Arch Ophthalmol       Date:  1992-02

Review 9.  Glucocorticoid therapy and ocular hypertension.

Authors:  Adnan Dibas; Thomas Yorio
Journal:  Eur J Pharmacol       Date:  2016-07-05       Impact factor: 4.432

10.  Spatiotemporal expression pattern of ceramide kinase-like in the mouse retina.

Authors:  Sharon Vekslin; Tamar Ben-Yosef
Journal:  Mol Vis       Date:  2010-12-03       Impact factor: 2.367

View more
  2 in total

1.  Nanoencapsulated hybrid compound SA-2 with long-lasting intraocular pressure-lowering activity in rodent eyes.

Authors:  Dorota L Stankowska; J Cameron Millar; Bindu Kodati; Sumita Behera; Renuka M Chaphalkar; Tam Nguyen; Kytai T Nguyen; Raghu R Krishnamoorthy; Dorette Z Ellis; Suchismita Acharya
Journal:  Mol Vis       Date:  2021-01-16       Impact factor: 2.367

2.  Novel Thiol Containing Hybrid Antioxidant-Nitric Oxide Donor Small Molecules for Treatment of Glaucoma.

Authors:  Charles E Amankwa; Sudershan R Gondi; Adnan Dibas; Courtney Weston; Arlene Funk; Tam Nguyen; Kytai T Nguyen; Dorette Z Ellis; Suchismita Acharya
Journal:  Antioxidants (Basel)       Date:  2021-04-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.